Clinical Trials Logo

Refractory Neoplasm clinical trials

View clinical trials related to Refractory Neoplasm.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04239092 Active, not recruiting - Neuroblastoma Clinical Trials

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Start date: June 5, 2020
Phase: Phase 1
Study type: Interventional

9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.

NCT ID: NCT03678883 Active, not recruiting - Cancer Clinical Trials

9-ING-41 in Patients With Advanced Cancers

Start date: January 4, 2019
Phase: Phase 2
Study type: Interventional

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.